Envoy Medical, Inc. COCH
7.09 USD -0.03 (-0.35%)
Nov 5, 2026, 11:13 AM EST
6.62 Day range 7.25
3.63 52-week range 9.54
- YTD
- +7.19%
- 1 year
- -3.08%
- Market cap
- 54.83M
- Revenue (ttm)
- 302.00K
- EPS (ttm)
- -7.60
- Shares out
- 20.24M
- Forward P/E
- -1.43
- YTD return
- +7.19%
- 1-year return
- -3.08%
- Volume
- 13.93K
- Avg volume
- 12.48K
- Open
- 7.13
- Previous close
- 7.11
- Day's range
- 6.62 – 7.25
- 52-week range
- 3.63 – 9.54
- Beta
- 2.36
- Price target
- 6.50 (-8.3%)
- Earnings date
- Aug 12, 2024
2Y -14.41 (-67.02%)
Key statistics
- Enterprise value
- 48.59M
- PEG ratio
- 0.00
- Price / sales
- 107.26
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 7.90%
- Free cash flow
- -8.05M
- Total cash
- 1.75M
- Total debt
- 8.59M
- Return on equity
- 0.00%
- Short % of float
- 0.65%
- 50-day average
- 2.25
- 200-day average
- 3.10
Analyst view
Price target (mean) 6.50 -8.3% downside
Now 7.09
- Target (low)
- 5.00
- Target (mean)
- 6.50
- Target (high)
- 9.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.31333.
Financials — quick view
COCH Revenue — quarterly 51.00K
COCH Net income — quarterly -5.98M
COCH EPS — quarterly -0.70
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.27 | -0.37 | -0.10 | -37.04% |
| Aug 12, 2024 | Jun 1, 2024 | -0.24 | — | — | — |
| Aug 12, 2024 | Jun 1, 2024 | -0.24 | -0.27 | -0.03 | -12.50% |
| May 15, 2024 | Mar 1, 2024 | -0.19 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.19 | -0.32 | -0.13 | -68.42% |
| Apr 5, 2024 | Dec 1, 2023 | -0.19 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 6, 2024 | Ascendiant Capital | main | Buy | Buy |
| Oct 14, 2024 | Brookline Capital | init | — | Buy |
| Sep 3, 2024 | Ascendiant Capital | main | Buy | Buy |
| Jun 24, 2024 | Ascendiant Capital | init | — | Buy |
| Apr 3, 2024 | Lake Street | main | Buy | Buy |
| Dec 21, 2023 | Northland Capital Markets | init | — | Outperform |
About Envoy Medical, Inc.
Envoy Medical, Inc., a hearing health company, focuses on providing medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- envoymedical.com
News
Envoy Medical, Inc. (COCH) Reports Q3 Loss, Tops Revenue Estimates 
Envoy Medical Q3 2026 Earnings Call Transcript 
Envoy Medical Q3 EPS $(0.50) Beats $(0.67) Estimate, Sales $66.000K Miss $86.667K Estimate 
Envoy Medical Reports Third Quarter 2026 Results and Highlights Continued Progress 
Envoy Medical Updates Third Quarter 2026 Earnings Call Time to 8:00 A.M. ET on Thursday, November 5th 
Envoy Medical to Report Third Quarter 2026 Financial Results on Thursday, November 5th 
Envoy Medical Announces 1-For-10 Reverse Stock Split, Effective Oct. 26 
Envoy Medical Announces Reverse Stock Split - Envoy Medical Surpasses 6-Month Follow-Up Visit Milestone For Pivotal Clinical Trial Evaluating Investigational Fully Implanted Acclaim Cochlear Implant; Expects To Submit Final Clinical PMA Module By End Of Q2 2027
Envoy Medical Hits Six-Month Milestone, Marks Halfway Point in Final Stage of Data Collection, and Highlights Differentiated Device Design
Your note
Sign in to keep a note on COCH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANZU SPAC GP I L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 28, 2023 | 0 |
| DEWBREY DIANE L | Director | Conversion of Exercise of derivative security | Sep 28, 2023 | 25,000 |
| HIRSCH DANIEL J | Chief Financial Officer | Conversion of Exercise of derivative security | Sep 28, 2023 | 25,000 |
| HUSKINS PRIYA CHERIAN | Director | Conversion of Exercise of derivative security | Sep 28, 2023 | 25,000 |
| KANTOR SUSAN J. | Director | Conversion of Exercise of derivative security | Sep 28, 2023 | 25,000 |
| LUCAS BRENT T | Chief Executive Officer | Purchase | Nov 20, 2023 | 131,338 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Atlas Merchant Capital LLC | 2.74% | 555,527 | 888.84K | Sep 29, 2024 |
| Vanguard Group Inc | 0.92% | 185,961 | 297.54K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.44% | 88,544 | 141.67K | Sep 29, 2024 |
| HighPoint Advisor Group LLC | 0.19% | 38,662 | 61.86K | Sep 29, 2024 |
| Corient Private Wealth LLC | 0.19% | 38,162 | 61.06K | Sep 29, 2024 |
| Morgan Stanley | 0.16% | 31,541 | 50.47K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.55% | 112,140 | 179.42K | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 0.35% | 70,033 | 112.05K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.20% | 39,484 | 63.17K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.07% | 13,277 | 21.24K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.07% | 14,692 | 23.51K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.07% | 13,654 | 21.85K | Oct 30, 2024 |